Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Operating Expenses: 2014-2024

Historic Operating Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to $208.6 million.

  • Spyre Therapeutics' Operating Expenses rose 2.70% to $56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $213.6 million, marking a year-over-year increase of 10.57%. This contributed to the annual value of $208.6 million for FY2024, which is 14.24% down from last year.
  • Spyre Therapeutics' Operating Expenses amounted to $208.6 million in FY2024, which was down 14.24% from $243.2 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' Operating Expenses ranged from a high of $243.2 million in FY2023 and a low of $81.5 million during FY2020.
  • For the 3-year period, Spyre Therapeutics' Operating Expenses averaged around $179.6 million, with its median value being $208.6 million (2024).
  • As far as peak fluctuations go, Spyre Therapeutics' Operating Expenses spiked by 179.17% in 2023, and later decreased by 14.24% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Operating Expenses (Yearly) stood at $81.5 million in 2020, then rose by 3.57% to $84.4 million in 2021, then climbed by 3.23% to $87.1 million in 2022, then soared by 179.17% to $243.2 million in 2023, then fell by 14.24% to $208.6 million in 2024.